Loading
CAR-T Cell Therapy Research / Virus-based Gene Therapy Research · Journal article
Frontiers in Cell and Developmental Biology · September 4, 2026
A consensus or society position rather than new primary data.
This is a narrative mini-review that synthesizes the biological rationale, early clinical experience, and current obstacles for CAR-T therapies targeting oncofetal antigens. While oncofetal antigens show biological promise due to their developmentally restricted and re-emergent expression in malignancy, clinical results have been promising in select hematologic and CNS tumours (neuroblastoma, diffuse midline gliomas) but remain modest in solid malignancies. The authors propose that integration of developmental biology, tumor evolution, and immuno-engineering principles will be needed to improve efficacy.
Narrative mini-review. Patients with malignancies including neuroblastoma, diffuse midline gliomas, and other solid tumours; review scope.
Multiple oncofetal antigens have entered early-phase clinical trials as CAR-T cell targets with promising results in neuroblastoma and diffuse midline gliomas. Antitumor efficacy in most solid malignancies has been modest, reflecting intratumoral antigen heterogeneity, immune suppression, CAR-T cell exhaustion, and limited persistence. Oncofetal antigens are tightly linked to cellular plasticity, stem-like programs, immune evasion, and resistance to cytotoxic therapies.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
This review contextualizes oncofetal antigens as emerging but not yet mature targets for CAR-T therapy. Clinicians and researchers should recognize the biological promise in selected tumour types while acknowledging current limitations in solid tumours and the need for combination and engineering strategies to improve efficacy.
A narrative mini-review synthesizing biological rationale, clinical trial experience, and emerging strategies for oncofetal antigen-targeted CAR-T therapies, offering expert perspective on opportunities and limitations rather than novel empirical findings.
As stated by the source record.
This review contextualizes oncofetal antigens as emerging but not yet mature targets for CAR-T therapy. Clinicians and researchers should recognize the biological promise in selected tumour types while acknowledging current limitations in solid tumours and the need for combination and engineering strategies to improve efficacy.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no reported figures. That is a gap in the analysis, not a judgement about the study.
Oncofetal antigens are emerging targets for chimeric antigen receptor (CAR)-based immunotherapies due to their developmentally restricted expression and frequent re-emergence in malignant cells. These antigens are tightly linked to cellular plasticity, stem-like programs, immune evasion, and resistance to cytotoxic therapies, making them biologically compelling targets. Multiple oncofetal antigens have entered early-phase clinical trials as CAR-T cell targets with promising results in several cancers including neuroblastoma and diffuse midline gliomas. However, antitumor efficacy in most solid malignancies has thus far been modest. This reflects shared obstacles, including low-level expression in normal tissues, intratumoral antigen heterogeneity, immune suppression within the tumor microenvironment, CAR-T cell exhaustion, and limited persistence. In this Mini-Review, we discuss the biological foundations of oncofetal antigen expression, synthesize clinical and pre-clinical experience targeting these antigens with CAR-T cell therapies, and highlight emerging engineering and combination strategies designed to overcome current limitations. We propose that integrating principles from developmental biology, tumor evolution, and immuno-engineering will be essential to unlocking the therapeutic potential of oncofetal antigen-directed CAR-T therapies in solid tumors.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.